icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype 1 HCV patients with cirrhosis: Interim analysis from SOUND-C2
 
 
  Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
 
Vicente Soriano,1 Ed Gane,2 Peter Angus,3 Felix Stickel,4 Jean-Pierre Bronowicki,5 Stuart Roberts,6 Michael Manns,7 Stefan Zeuzem,8 Luyan Dai,9 Wulf Boecher,10 Jerry Stern9 and Federico Mensa9 1Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain; 2Auckland Clinical Studies, Auckland, New Zealand; 3Austin Health, Liver Transplant Unit, Heidelberg, Australia; 4Universitätsklinik für Viszerale Chirurgie und Medizin, Bern, Switzerland; 5Hopital de Brabois, Vandoeuvre, France; 6Alfred Hospital, Department of Gastroenterology, Melbourne, Australia; 7Medizinische Hochschule Hannover, Hannover, Germany; 8Klinikum der J. W. Goethe-Universität, Frankfurt am Main, Germany; 9Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 10Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif